$0.14
-0.01 (-5.88%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PHGE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study With Phage for CF Subjects With Pseudomonas Lung InfectionNCT06998043Change in sputum Pseudomonas aeruginosa (PsA) burden at 8 weeks (EOT)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Biological: BX004 · Other: Placebo | Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF) | 63 | Mar 2026 | 2025-07-22 |
| Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary InfectionNCT05010577Safety and tolerabilityRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: BX004-A, Placebo | Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis | 43 | 2024-03-10actual | 2025-07-18 |
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic DermatitisNCT05240300Safety and tolerability: adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Study did not start enrollment due to business reasons | Biological: BX005-A · Other: Placebo | Atopic Dermatitis | 0 | Jun 2023 | 2025-08-03 |
| A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy AdultsNCT04737876Safety and Tolerability: adverse eventsRandomized · Single-masked · Other | Phase 1 | Completed | Biological: BX002-A · Other: Placebo | Healthy Volunteers | 18 | 2020-12-21actual | 2022-01-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19